190 results
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
29 Apr 24
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
6:14am
among patients treated with fruquintinib, regardless of the prior types of therapies they received. Fruquintinib demonstrated a manageable safety … for its potential use as part of a combination therapy. Fruquintinib has demonstrated a manageable safety profile and is being investigated
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
5 Apr 24
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
6:03am
- Drug Resistance 2: Ras GTPase)
Monday, April 8, 2024
Safety and Efficacy of Sovleplenib (HMPL-523), a Syk Inhibitor, in Patients with Relapsed … criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
2 Apr 24
Current report (foreign)
6:03am
target inhibition, and flexibility for its potential use as part of a combination therapy. Fruquintinib has demonstrated a manageable safety profile … secondary efficacy endpoints and showed consistent benefit among a total of 734 patients treated with fruquintinib. Safety profiles were consistent
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
28 Mar 24
Current report (foreign)
6:02am
skipping alterations.
Preliminary efficacy and safety data from the first-line cohort of the confirmatory Phase IIIb clinical trial (NCT04923945 … treated patients. The safety profile was tolerable and no new safety signals were observed. The most common drug-related treatment-emergent adverse events
6-K
EX-99.1
HCM
HUTCHMED (China) Limited
22 Mar 24
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
6:06am
of the registration stage of the study is to confirm the safety and efficacy of sovleplenib in adult patients with wAIHA. The primary endpoint … and safety profile of sovleplenib, HUTCHMED’s ability to fund, implement and complete its further clinical development and commercialization plans
6-K
EX-99.1
q3fd1xfvql
28 Feb 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
6:47am
6-K
EX-99.1
umcuq
7 Feb 24
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
6:43am
6-K
EX-99.1
2dee4sk8n9r9zp15
2 Feb 24
HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership
6:15am
6-K
EX-99.1
y7cc 3ujbcl9m0
30 Jan 24
HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer
6:17am
6-K
EX-99.1
7k5jn dmj0
11 Jan 24
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
6:02am
6-K
EX-99.1
gp56 qutc7wr1
13 Dec 23
Current report (foreign)
6:04am
6-K
EX-99.2
8ahip iw55u05xay
13 Dec 23
Current report (foreign)
6:04am
6-K
EX-99.1
d3jewc3lmvn ir2
1 Dec 23
HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses
6:03am
6-K
EX-99.1
3mhaa j4bssd3v
9 Nov 23
HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer
6:03am
6-K
EX-99.1
7q5hxm7t76s4lzjqz1
16 Oct 23
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023
6:05am
6-K
EX-99.2
ewc1p7j7ir uif2psr
29 Sep 23
Current report (foreign)
6:20am
6-K
EX-99.2
c1xe w0fd
12 Sep 23
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
6:10am
6-K
EX-99.1
57g856r57xb6qofmd6n
12 Sep 23
HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China
6:10am
6-K
EX-99.1
as4317755c7pfjan5
29 Aug 23
HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer
6:12am